 "Fresenius Kabi in talks with Akorn for takeover")
Akorn Inc, the US-based specialty generic pharmaceutical company, has confirmed that it is currently in discussions with Fresenius Kabi, a subsidiary of Fresenius SE & Co KGaA, concerning a potential acquisition of Akorn.
Entry into a formal agreement with respect to a transaction remains subject to, among other things, approval by the executive board and supervisory board of Fresenius Management SE and the board of directors of Akorn.
There can be no assurance any transaction will result from these discussions, or as to the terms of any such transaction. Neither Fresenius nor Akorn intend to make any additional comments regarding these negotiations unless and until it is appropriate to do so, or a formal agreement has been reached.
Akorn Inc is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur (Illinois); Somerset (New Jersey); Amityville (New York); Hettlingen (Switzerland) and Paonta Sahib (India) that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals.
Fresenius Kabi is a global health care company that specialises in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%